| Literature DB >> 15994883 |
A C Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, H Olsson, O Johannsson, A Borg, B Pasini, P Radice, S Manoukian, D M Eccles, N Tang, E Olah, H Anton-Culver, E Warner, J Lubinski, J Gronwald, B Gorski, H Tulinius, S Thorlacius, H Eerola, H Nevanlinna, K Syrjäkoski, O-P Kallioniemi, D Thompson, C Evans, J Peto, F Lalloo, D G Evans, D F Easton.
Abstract
A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.Entities:
Mesh：
Year: 2005 PMID： 15994883 PMCID： PMC1736090 DOI： 10.1136/jmg.2004.024133
Source DB: PubMed Journal: J Med Genet ISSN： 0022-2593 Impact factor: 6.318